Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase I Study Cisplatin and Gemcitabine for Recurrent Cervix Cancer Following Primary Radiotherapy

Phase I Study Cisplatin and Gemcitabine for Recurrent Cervix Cancer Following Primary Radiotherapy. 2000; 19(ASCO 2000):A:1571.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.